Olorofim in Early Coccidioidal Meningitis

This research study is being conducted to learn more about the use of olorofim in Coccidioidal (Cocci) meningitis, a rare but serious fungal infection that affects the brain and spinal cord. The study is exploratory, meaning that early information is being gathered to better understand the effectiveness of olorofim in coccidioidal meningitis in its early stages. The study plans to enroll approximately 10 to 12 participants who have been recently diagnosed-within the last 4 to 8 weeks-and who do not have a ventriculoperitoneal (VP) shunt, a medical device sometimes used to relieve pressure in the brain. Participants will be followed for approximately 6 months, during which health information will be collected to evaluate disease progression and response to treatment. Participants may have the opportunity to enroll in the olorofim Managed Access Program to continue treatment after completion of the study period.

NCT Number	NCT07385638
Lead Sponsor	Fariba Donovan Collaborators: F2G Biotech GmbH
Conditions	Coccidioidal Meningitis
Enrollment	12 participants
Start Date	2026-06-01
Primary Completion	2027-03-15 (estimated)
Study Completion	2027-06-15 (estimated)
Updated on ClinicalTrials.gov	2026-07-27